Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
a technology for ebola virus and immune response, applied in the field of ebola virus vaccines, can solve the problems of ineffective immune response elicitation by traditional active and passive immunization methods, and achieve the effect of preventing the spread of ebola virus
Inactive Publication Date: 2005-12-22
NABEL GARY +1
View PDF1 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Benefits of technology
[0005] The present invention also provides methods for immunizing a subject against disease caused by infection with Ebola virus comprising administering to the subject an immunoeffective amount of an Ebola virus vaccine. Administration can be by any of the ro...
Problems solved by technology
Previous attempts to elicit protective immune responses against Ebola virus usin...
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
specific example
I. Results
[0048] Immune response to viral gene products in mice. To characterize immune responses to selected Ebola virus proteins, eukaryotic expression vector plasmids were injected into mice. The cytomegalovirus (CMV) immediate early region 1 enhancer was used to stimulate transcription because ft directs high levels of gene expression in muscle. Manthorpe, M. et al., Hum. Gene. Ther. 4:419-431 (1993). cDNAs encoding an abundant structural protein, the major viral nucleocapsid phosphoprotein (NP), the secreted glycoprotein (sGP), or the membrane-associated glycoprotein (GP) were inserted. Alternative forms of GP were chosen because it had been postulated that the transmembrane protein contained a protein sequence motif also found in oncogenic retroviruses that might suppress immune responses. Burkreyev, A. A. et al., FEBS. Lett. 323:183-187 (1993); Cianciolo, G. J. et al., Science 230:453-455 (1985); Harris, D. T. et al., J. Immunol. 138:889-894 (1987); Volchkov, V. E. et al., ...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Property
Measurement
Unit
Time
aaaaa
aaaaa
Composition
aaaaa
aaaaa
Frequency
aaaaa
aaaaa
Login to view more
Abstract
Ebola virus vaccines comprising nucleic acid molecules encoding Ebola viral proteins are provided. In one embodiment, the nucleic acid molecule encodes the transmembrane form of the viral glycoprotein (GP). In another embodiment, the nucleic acid molecule encodes the secreted form of the viral glycoprotein (sGP). In yet another embodiment, the nucleic acid molecule encodes the viral nucleoprotein (NP). Methods for immunizing a subject against disease caused by infection with Ebola virus are also provided.
Description
FIELD OF THE INVENTION [0001] The present invention relates generally to viral vaccines and, more particularly, to Ebola virus vaccines and methods of protecting against disease caused by infection with Ebola virus. BACKGROUND OF THE INVENTION [0002] The Ebola viruses, and the genetically-related Marburg virus, are filoviruses associated with outbreaks of highly lethal hemorrhagic fever in humans and primates in North America, Europe, and Africa. Peters, C. J. et al., Filoviridae: Marburg and Ebola Viruses. in Fields Virology. (eds., Fields, B. N., Knipe, D. M. & Howley, P. M.) 1161-1176 (Philadelphia, Lippincott-Raven, 1996); Peters, C. J. et al, Semin. Virol. 5:147-154 (1994). Ebola viruses are negative-stranded RNA viruses comprised of four subtypes, including those described in the Zaire, Sudan, Reston, and Ivory Coast episodes. Sanchez, A. et al., PNAS (USA) 93:3602-3607 (1996). Although several subtypes have been defined, the genetic organization of these viruses is similar, e...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more